All News #Library
Others
AceLink Completes 6-Month Primary Ph of AL01211 in Fabry
14 Aug 2025 //
BUSINESSWIRE
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
10 Aug 2023 //
BUSINESSWIRE
AceLink Therapeutics approved to begin Fabry disease drug trial
22 Jun 2023 //
CLINICAL TRIALS ARENA
AceLink Receives FDA Clearance to Initiate a Ph2 Study of AL1211
21 Jun 2023 //
BUSINESSWIRE

Market Place
Sourcing Support